TITLE

Disparities found in PSA testing, prostate cancer care

PUB. DATE
September 2008
SOURCE
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p40
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article examines the disparities in prostate specific antigen (PSA) testing and prostate cancer care cited by different studies. Chuck Scales and his colleagues learned that prostate cancer screening remains potentially suboptimal among high-risk men and found discrepancies in sociodemographic characteristics in the PSA test. Another study showed that PSA-based screening is less effective for obese men.
ACCESSION #
34154575

 

Related Articles

  • Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer.  // Evidence Based Medicine;Aug2009, Vol. 14 Issue 4, p105 

    The article reports on the study related to the periodic screening with prostate-specific antigen (PSA) testing to reduce mortality from prostate cancer. The study was conducted to 162,243 men ranging from 55 to 69 years-old across Europe. Meanwhile, the result shows that in most centres, a...

  • Screening digital rectal examination and prostate cancer mortality: a case-control study. Richert-Boe, Kathryn E.; Humphrey, Linda L.; Glass, Andrew G.; Weiss, Noel S. // Journal of Medical Screening;Jun1998, Vol. 5 Issue 2, p99 

    Background Prostate cancer is the second most common cause of death from cancer in men in the United States. Digital rectal examination is the oldest and most commonly used screening test for prostate cancer, but as yet there are no studies which demonstrate its effectiveness. Methods A...

  • Is one set of transrectal sextant biopsies enough to rule out prostate cancer? A prospective evaluation. Zlotta, A R; Djavan, B; Ekane, S; Marberger, M; Schulman, C C // Prostate Cancer & Prostatic Diseases;1999 Supplement 3, Vol. 2 Issue 4, pS36 

    Evaluates prostate-specific antigen parameters in patients in whom prostate cancer was found after the first and second sets of biopsies. Methods; Results; Conclusion.

  • Best tests and care for prostate cancer.  // Consumer Reports on Health;Aug2000, Vol. 12 Issue 8, p1 

    Focuses on the diagnosis and treatment of prostate cancer in the United States. Objections of the government task force and physicians regarding the use of prostate-specific antigen test (PSA); Guidelines for the proper use of PSA; Risks factors of prostate cancer; Statistics on the incidence...

  • False-positive screening results in the Finnish prostate cancer screening trial. Kilpeläinen, T. P.; Tammela, T. L. J.; Määttänen, L.; Kujala, P.; Stenman, U.-H.; Ala-Opas, M.; Murtola, T. J.; Auvinen, A. // British Journal of Cancer;2/10/2010, Vol. 102 Issue 3, p469 

    Background:There is evidence that prostate cancer (PC) screening with prostate-specific antigen (PSA) serum test decreases PC mortality, but screening has adverse effects, such as a high false-positive (FP) rate. We investigated the proportion of FPs in a population-based randomised screening...

  • Rapid progression of prostate cancer in men with a BRCA2 mutation. Narod, S A; Neuhausen, S; Vichodez, G; Armel, S; Lynch, H T; Ghadirian, P; Cummings, S; Olopade, O; Stoppa-Lyonnet, D; Couch, F; Wagner, T; Warner, E; Foulkes, W D; Saal, H; Weitzel, J; Tulman, A; Poll, A; Nam, R; Sun, P; Hereditary Breast Cancer Study Group // British Journal of Cancer;7/22/2008, Vol. 99 Issue 2, p371 

    Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and...

  • Why do men refuse or attend population-based screening for prostate cancer? Nijs, H. G. T.; Essink-Bot, M. L.; DeKoning, H. J.; Kirkels, W. J.; Schröder, F. H. // Journal of Public Health Medicine;Sep2000, Vol. 22 Issue 3, p312 

    Background. The aims of this study were to investigate the motives for refusing or attending population-based screening for prostate cancer, in relation to various background characteristics.

  • The Status of Prostate Specific Antigen and Prostate Cancer Screening in 2009. Schröder, Fritz H.; Roobol, Monique J. // AUANews;Oct2009, Vol. 14 Issue 10, p1 

    The article discusses screening for prostate cancer (PC) and prostate specific antigen (PSA). It references a 2009 report from the European Randomized Study of Screening for Prostate Cancer (ERSPC) to apply the results for health care providers and men considering screening. Also included are...

  • An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Junxia Min; Zaslavsky, Alexander; Fedele, Giuseppe; McLaughlin, Sara K.; Reczek, Elizabeth E.; De Raedt, Thomas; Guney, Isil; Strochlic, David E.; MacConaill, Laura E.; Beroukhim, Rameen; Bronson, Roderick T.; Ryeom, Sandra; Hahn, William C.; Loda, Massimo; Cichowski, Karen // Nature Medicine;Mar2010, Vol. 16 Issue 3, p286 

    Metastasis is responsible for the majority of prostate cancer–related deaths; however, little is known about the molecular mechanisms that underlie this process. Here we identify an oncogene–tumor suppressor cascade that promotes prostate cancer growth and metastasis by...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics